EpCAM Nuclear Localization Identifies Aggressive Thyroid Cancer and is a Marker for Poor Prognosis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Jun 29

PMID 20579375

Citations 42

Authors

Ranju Ralhan

Jun Cao

Terence Lim

Christina MacMillan

Jeremy L Freeman

Paul G Walfish

Affiliations

Soon will be listed here.

Abstract

Background: Proteolytic cleavage of the extracellular domain (EpEx) of Epithelial cell adhesion molecule (EpCAM) and nuclear signaling by its intracellular oncogenic domain Ep-ICD has recently been implicated in increased proliferation of cancer cells. The clinical significance of Ep-ICD in human tumors remains an enigma.

Methods: EpEx, Ep-ICD and beta-catenin immunohistochemistry using specific antibodies was conducted on 58 archived thyroid cancer (TC) tissue blocks from 34 patients and correlated with survival analysis of these patients for up to 17 years.

Results: The anaplastic (ATC) and aggressive thyroid cancers showed loss of EpEx and increased nuclear and cytoplasmic accumulation of Ep-ICD. In contrast, the low grade papillary thyroid cancers (PTC) showed membranous EpEx and no detectable nuclear Ep-ICD. The ATC also showed concomitant nuclear expression of Ep-ICD and beta-catenin. Kaplan-Meier Survival analysis revealed reduced overall survival (OS) for TC patients showing nuclear Ep-ICD expression or loss of membranous EpEx (p < 0.0004), median OS = 5 months as compared to 198 months for patients who did not show nuclear Ep-ICD or demonstrated only membranous EpE.

Conclusion: We report reciprocal loss of membrane EpEx but increased nuclear and cytoplasmic accumulation of Ep-ICD in aggressive TC; nuclear Ep-ICD correlated with poor OS of TC patients. Thus nuclear Ep-ICD localization may serve as a useful biomarker for aggressive TC and may represent a novel diagnostic, prognostic and therapeutic target for aggressive TC.

Citing Articles

Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model.

Ghiandai V, Grassi E, Gazzano G, Fugazzola L, Persani L Cancer Cell Int. 2024; 24(1):196.

PMID: 38835027 PMC: 11149206. DOI: 10.1186/s12935-024-03378-2.

Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment.

Logghe T, van Zwol E, Immordino B, Van den Cruys K, Peeters M, Giovannetti E Cancers (Basel). 2024; 16(3).

PMID: 38339258 PMC: 10854776. DOI: 10.3390/cancers16030505.

Molecules promoting circulating clusters of cancer cells suggest novel therapeutic targets for treatment of metastatic cancers.

Rozenberg J, Buzdin A, Mohammad T, Rakitina O, Didych D, Pleshkan V Front Immunol. 2023; 14:1099921.

PMID: 37006265 PMC: 10050392. DOI: 10.3389/fimmu.2023.1099921.

Clinicopathological Profile of Medullary Thyroid Carcinoma-Could We Predict Aggressive Behavior?.

Giusca S, Andriescu E, Caruntu I, Ciobanu D Biomedicines. 2023; 11(1).

PMID: 36672624 PMC: 9855433. DOI: 10.3390/biomedicines11010116.

Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside.

Liu Y, Wang Y, Sun S, Chen Z, Xiang S, Ding Z Exp Hematol Oncol. 2022; 11(1):97.

PMID: 36369033 PMC: 9650829. DOI: 10.1186/s40164-022-00352-4.

References

Are C, Shaha A . Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006; 13(4):453-64. DOI: 10.1245/ASO.2006.05.042. View

Rocha A, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira M, Sobrinho-Simoes M . E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology. 2003; 42(6):580-7. DOI: 10.1046/j.1365-2559.2003.01642.x. View

Pasieka J . Anaplastic thyroid cancer. Curr Opin Oncol. 2002; 15(1):78-83. DOI: 10.1097/00001622-200301000-00012. View

El-Sahwi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-Khalaf M . Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther. 2010; 9(1):57-66. PMC: 2806489. DOI: 10.1158/1535-7163.MCT-09-0675. View

Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O . The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004; 23(34):5748-58. DOI: 10.1038/sj.onc.1207610. View

Antolovic D, Galindo L, Carstens A, Rahbari N, Buchler M, Weitz J . Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol. 2010; 10:35. PMC: 2868015. DOI: 10.1186/1472-6750-10-35. View

Li H, Pamukcu R, Thompson W . beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther. 2003; 1(6):621-5. DOI: 10.4161/cbt.309. View

Trzpis M, McLaughlin P, de Leij L, Harmsen M . Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007; 171(2):386-95. PMC: 1934518. DOI: 10.2353/ajpath.2007.070152. View

Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P . Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat. 2009; 123(3):701-8. PMC: 3042397. DOI: 10.1007/s10549-009-0671-z. View

10.

Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M . Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer. 2007; 6:62. PMC: 2140063. DOI: 10.1186/1476-4598-6-62. View

11.

Ensinger C, Kremser R, Prommegger R, Spizzo G, Schmid K . EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. J Immunother. 2006; 29(5):569-73. DOI: 10.1097/01.cji.0000211303.52503.da. View

12.

Morin P . beta-catenin signaling and cancer. Bioessays. 1999; 21(12):1021-30. DOI: 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P. View

13.

Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S . Beta-catenin expression in human cancers. Am J Pathol. 1996; 148(1):39-46. PMC: 1861624. View

14.

Ogasawara N, Tsukamoto T, Mizoshita T, Inada K, Cao X, Takenaka Y . Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology. 2006; 49(6):612-21. DOI: 10.1111/j.1365-2559.2006.02560.x. View

15.

Bian Y, Osterheld M, Bosman F, Fontolliet C, Benhattar J . Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol. 2000; 114(4):583-90. DOI: 10.1309/3QLC-5MF1-JYXU-A5XX. View

16.

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

17.

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

18.

Stingl J, Eaves C, Zandieh I, Emerman J . Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat. 2001; 67(2):93-109. DOI: 10.1023/a:1010615124301. View

19.

Raffel A, Eisenberger C, Cupisti K, Schott M, Baldus S, Hoffmann I . Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol. 2010; 162(2):391-8. DOI: 10.1530/EJE-08-0916. View

20.

Smallridge R, Marlow L, Copland J . Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2008; 16(1):17-44. PMC: 2829440. DOI: 10.1677/ERC-08-0154. View